#news #biotech Concert rethinks R&D plans after loss in Incyte patent case

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Concert rethinks R&D plans after loss in Incyte patent case .Concert Pharmaceuticals is reassessing whether to expand CTP-543 into additional indications after its attempt to challenge an Incyte patent failed. The setback leaves Concert committed to taking the drug forward in alopecia areata but uncertain of its future beyond the indication.

from FierceBiotech: Biotech http://ift.tt/2CWf1Lo